You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations
Sign In
{{'GLOBAL_MESSAGE_HEADLINE' | translate}}
{{'GLOBAL_MESSAGE_CHOOSE_LANG' | translate}}
en
日本語
中文
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'GLOBAL_MESSAGE_SET_COUNTRY' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM' | translate}}
{{'ELOQUA_BANNER_DECLINE_CONFIRM_CLOSE' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}
UNLOCKING THE POTENTIAL OF BLOOD
{{'MP_LVL1NAV_PRODUCTS_SERVICES' | translate}}
{{d.Title}}
{{psData[masterIndex].Blurb}}
{{s.Title}}
{{l.Title}}
{{n.Title}}
{{n.Blurb}}
{{s.Title}}
{{l.Title}}
Welcome, {{userName}}
{{'MP_HEADER_LOG_IN' | translate}}
{{countryCode}}
{{'SEARCH_MODAL_TITLE' | translate}}
{{'MP_LVL1NAV_PRODUCTS_SERVICES' | translate}}
{{c.Title}}
{{s.Title}}
{{l.Title}}
{{n.Title}}
{{s.Title}}
{{l.Title}}
Page Content
WEBINAR: COVID-19 experts discuss exosomes and MSCs for experimental treatment for ARDS in COVID-19
Register now for this June 4, 2020 event
New Reveos
®
System eLearning Course
Explore the Reveos Automated Blood Processing System
Terumo BCT receives first device FDA Emergency Use Authorization (EUA) to treat acute respiratory failure
in COVID-19 patients
Terumo BCT COVID-19 Response & Business Continuity
Keeping you informed.
Leverage our expertise, data and technology to achieve your goals.
Cell Therapy Technologies
Automated solutions to streamline and optimize your cell and gene therapy development.
Are you ready to meet the FDA guidance?
With the FDA’s bacterial risk control strategies guidance released, it’s time to compare your options.
Global Connection:
Learn About Our Commitment to Social Responsibility
QUICK LINKS
Get Product Support
Find Technical Documents
Find Certificates of Compliance
Get Training
Start a Career With Us
LATEST NEWS
Terumo BCT’s Mirasol reduces the virus causing COVID-19 below the limit of detection in plasma and platelets
Terumo Donates USD 2.4 Million in Cash and Products to Support COVID-19 Pandemic Relief Efforts Worldwide
Terumo BCT’s Mirasol Shows Efficacy Against Virus Causing COVID-19 in Plasma and Platelets
Terumo BCT and Marker Therapeutics received the first device FDA Emergency Use Authorization (EUA) to treat acute respiratory failure in COVID-19 patients
Terumo BCT Message: COVID-19
Terumo BCT’s Mirasol
®
Pathogen Reduction Technology (PRT) System Demonstrates Reduced Risk of Transfusion Transmission of MERS-CoV, a strain of Coronavirus
{{'SEARCH_MODAL_TITLE' | translate }}
{{s.Query|stripSpecialChars}}
{{'SEARCH_MODAL_OR' | translate }}
{{'SEARCH_MODAL_BROWSE' | translate }}
{{'SEARCH_MODAL_PRODUCT' | translate }}
{{productCode.RefinementName}}
{{'SEARCH_MODAL_CATEGORY' | translate }}
{{categoryCode.RefinementName}}
{{'SEARCH_SMODAL_SEGMENT' | translate }}
{{segmentCode.RefinementName}}
{{'SEARCH_MODAL_SHOW_BROWSE_RESULTS' | translate }}
{{'SEARCH_MODAL_CHOOSE_LANGUAGE' | translate }}
{{'SEARCH_MODAL_CHANGE_LANGUAGE' | translate }}
{{$index+1}}. {{s.label}}